EAU 2026 hypogonadism guidelines — SHBG and calculated free T get formalized, the 12 nmol/L threshold stays, prostate cancer guidance is significantly revised.

What the EAU 2026 guideline is

The EAU Guidelines on Sexual and Reproductive Health (SRH) were first published in 2020 and are updated regularly by an international panel of urologists and andrologists. The 2026 document is a limited update of the 2025 publication, incorporating 116 updated studies across the Hypogonadism, Disorders of Ejaculation, Penile Curvature and Priapism sections (Uroweb). For clinicians treating men with low testosterone, Section 3 (Hypogonadism) is the operative reference — and this is where the substantive changes concentrated.

A companion peer-reviewed summary, authored by the EAU SRH panel led by Giovanni Corona and Andrea Salonia, was published in European Urology Focus online on May 23, 2026 (Corona et al., 2026). That paper walks through the measurement and biochemical confirmation recommendations in detail and is the citable version physicians should reference in charts and pathways.

The 12 nmol/L threshold stays

The 2026 update preserves the recommendation that a total testosterone level of ≤12 nmol/L (approximately 346 ng/dL) is the threshold for diagnosing symptomatic male hypogonadism (Corona et al., 2026). Total testosterone must be measured:

• In the morning, between 07:00 and 10:00 local time (strong recommendation, Section 3.3.5).
• In the fasting state.
• Using a reliable laboratory assay — LC-MS/MS is preferred, but immunoassays remain clinically acceptable when mass spectrometry is unavailable.

A single low reading is not a diagnosis. The 2026 update — like the 2025 version — continues to require symptomatic presentation plus repeat biochemical confirmation before starting therapy. That has been Aurafil's practice since day one, and nothing in this update changes it.

SHBG and calculated free T get promoted

The most clinically important measurement change is the formal expansion of SHBG and calculated free testosterone into everyday practice. From the 2026 recommendations (Corona et al., 2026):

• SHBG should be measured to prevent misdiagnosis of hypogonadism, particularly in men whose binding protein status may be altered.
• Calculated free testosterone, derived from total T, SHBG, and albumin, should be considered in any condition known to affect circulating SHBG — obesity, type 2 diabetes, hepatic disease, thyroid dysfunction, and anticonvulsant use, among others.
• Recent (limited-evidence) data support use of calculated free T even in men without SHBG-altering conditions.

The panel explicitly notes that immunoassay-based direct free testosterone measurement is unreliable and should not be substituted for calculated free T. Equilibrium dialysis remains the gold standard where research-grade measurement is required, but calculated free T using validated formulas (Vermeulen, Mazer) is what routine clinical practice will use (Corona et al., 2026).

Practically, that means an increasing share of men with borderline total testosterone but low free testosterone — often men with elevated SHBG from thyroid disease, hepatic disease, or normal aging — will now be captured as symptomatic hypogonadal under a formal European guideline framework, rather than being told their total is "in range" and dismissed.

Prostate cancer subsection — significantly revised

Subsection 3.5.4 on prostate cancer was one of the most heavily revised parts of the update. Two recommendations from other subsections were relocated here because the panel judged them more directly aligned with prostate cancer management (Uroweb). Three specific recommendations are now grouped in Section 3.5.9 (safety and monitoring in testosterone therapy):

1. TRT after prostatectomy — weak recommendation. Restrict treatment to patients with a low risk of recurrent prostate cancer after surgery. Treatment should start only after at least one year of follow-up with PSA < 0.01 ng/mL and no evidence of recurrence.
2. Active surveillance or non-surgical curative treatment — weak recommendation. Patients should be advised that safety data on TRT in this population are unclear.
3. Prostate-cancer-naïve patients on TRT — strong recommendation. Consider further diagnostic testing if there is a significant rise in PSA or an increase in PSA velocity during therapy.

Three notes on how to read those recommendations:

• A "weak" strength rating in EAU methodology means the panel judged the desirable and undesirable consequences of the intervention as closely balanced, or the certainty of the evidence as low. It is not a green light — it is an "in carefully selected patients, after shared decision-making, it may be considered."
• The one-year PSA < 0.01 ng/mL threshold is stricter than some U.S. urology practice patterns. This reflects the EAU panel's caution given the historical concern that TRT could accelerate residual disease.
• None of this replaces urologist evaluation. Aurafil does not initiate TRT in men with any active or recent prostate cancer history without direct urology co-management.

Fertility: TRT is not an infertility treatment

Section 3.4.2.f carries an unchanged but worth-repeating strong recommendation: do not use testosterone therapy for the treatment of male infertility, or in men wishing to be fathers (Uroweb). Exogenous testosterone suppresses the hypothalamic–pituitary–gonadal axis, which suppresses intratesticular testosterone production and impairs spermatogenesis. Men who want to preserve fertility while treating hypogonadism should be evaluated for alternatives (hCG, enclomiphene, or a combined approach), which is exactly why Aurafil offers a Fertility Preserve plan and an Enclomiphene Monotherapy plan as first-line options for men who want to protect fertility.

How this compares to the FDA's June proposal

Last week we covered the U.S. FDA and HHS June 18, 2026 proposed label changes — the largest overhaul of U.S. TRT labeling since 2015, which would remove the age-related hypogonadism limitation, narrow the prostate cancer contraindication to metastatic disease only, and revise the BPH warning. The EAU update lands in the same general direction — with important differences.

• Agreement: Both the FDA proposal and the EAU 2026 guideline move away from categorical restrictions and toward risk-stratified, symptomatic-based prescribing.
• Divergence on prostate cancer: The FDA proposal would narrow the formal contraindication to metastatic disease only. The EAU keeps a much narrower window — restricting TRT to low-risk post-prostatectomy patients with prolonged undetectable PSA, and explicitly calling the safety data unclear for active surveillance patients. Serious clinicians will practice closer to the EAU standard than the FDA label allows.
• Divergence on diagnosis: The EAU guideline is far more prescriptive about diagnostic workup — morning fasting total T, SHBG, calculated free T, LH/FSH to distinguish primary from secondary hypogonadism, and repeat measurement. The FDA label rewrite is silent on diagnostic method; that stays with clinicians and specialty guidelines.

The regulatory floor (FDA label) and the clinical standard-of-care ceiling (EAU/AUA/Endocrine Society guidelines) are two different documents that must both be respected. Aurafil practices to the guideline standard, not the label floor.

What this means for Aurafil patients

Concretely and honestly:

• Our intake bloodwork already includes total testosterone drawn between 07:00 and 10:00, along with SHBG, LH, FSH, estradiol, PSA (in age-appropriate patients), CBC, and comprehensive metabolic panel. We were already doing what the EAU 2026 update now formally recommends. Calculated free T using SHBG and albumin is the pathway we use for men with borderline or discordant total-T readings.
• The 12 nmol/L threshold (~346 ng/dL) is aligned with — but not identical to — the U.S. Endocrine Society's 264 ng/dL and the FDA-informed clinical cutoffs many U.S. programs use. Aurafil evaluates each case on total T, free T, symptoms, and comorbidities rather than on a single threshold. Men who are symptomatic with total T in the 300s and low free T are not dismissed as "in range."
• For men with any prostate cancer history — active, in surveillance, or post-treatment — we require urology co-management before starting TRT and follow the more conservative EAU 3.5.9 framework: one year post-prostatectomy with undetectable PSA and low recurrence risk before treatment is considered, and shared decision-making with the treating urologist.
• For men who want to preserve fertility, Fertility Preserve (TRT + hCG) and Enclomiphene Monotherapy remain the recommended options. The EAU guideline's strong recommendation against TRT-only for men wishing to be fathers reinforces why those two plans exist as first-line choices.
• We will not oversell what this update is. It is a limited update of an existing guideline — not a paradigm shift. But it is the most influential European guideline on hypogonadism, and it aligns closely with how Aurafil already practices.

The trend across both the FDA proposal and this EAU update is clear: regulatory bodies and specialty societies are converging on symptomatic, biochemically confirmed, risk-stratified TRT — not categorical bans and not categorical availability. Careful clinicians have practiced that way for a while. That's the standard Aurafil holds itself to.